Clinicopathologic study of 1176 salivary gland tumors in a Chinese population: Experience of one cancer center 1997–2007

YU-LONG WANG1,2, YONG-XUE ZHU1,2, TONG-ZHEN CHEN2,3, YU WANG1,2, GUO-HUA SUN1,2, LING ZHANG1,2, CAI-PING HUANG1,2, ZHUO-YING WANG1,2, QIANG SHEN1,2, DUAN-SHU LI1,2, YI WU1,2 & QING-HAI JI1,2

1Department of Head & Neck Surgery, Cancer Hospital, Fudan University, 2Department of Oncology, Shanghai Medical College, Fudan University and 3Department of Pathology, Cancer Hospital, Fudan University, Shanghai, China

Abstract

Conclusion: Chinese patients have a higher rate of lymphoepithelial carcinoma (LEC) and salivary duct carcinoma (SDC). Comprehensive use of diagnostic modalities, neck dissection, and postoperative radiation will improve the treatment results for salivary gland tumors (SGTs).

Objectives: To study the clinicopathological characteristics of SGTs in a Chinese population.

Methods: The records of SGT patients operated in a tertiary cancer hospital of China were retrieved.

Results: From December 1997 to December 2007, 289 malignant and 887 benign SGTs were operated at Cancer Hospital, Shanghai, China. Pleomorphic adenoma and Warthin’s tumor were the most common types of SGT. Mucoepidermoid carcinoma (24.6% of malignant cases) and adenoid cystic carcinoma (18.0%) were the most frequent malignant cases, followed by acinic cell carcinoma (12.1%), LEC (9.7%), and SDC (9.3%). The sensitivity and specificity of ultrasound scan, fine needle aspiration biopsy, and frozen section were 58.3 and 88.6%, 87.2 and 96.7%, 86.9 and 99.6%, respectively. Neck dissections and postoperative radiation were carried out for 48.6 and 48.0% of carcinomas, respectively. The percentage of tumors by pathologic TNM stage were 23.7% for stage I, 32.9% for stage II, 17.3% for stage III, and 26.1% for stage IV. The 5-year overall survival rate was 88.0%.

Keywords: Lymphoepithelial carcinoma, salivary duct carcinoma, incidence, fine needle aspiration, frozen section

Introduction

Salivary gland tumors (SGTs) are relatively uncommon lesions, accounting for less than 3% of all head and neck tumors [1,2]. In Shanghai city, China, the standardized incidence rates of malignant neoplasm of salivary glands are 0.45 and 0.40 per 100,000 women and men, respectively. The rarity of SGT coupled with its complex and changing classification over time has made the diagnosis and management challenging.

Geographical variations in the prevalent site and type of SGTs have been reported in the literature. In the Chinese population, especially from the Chinese mainland, there have been few reports of SGTs [3-8].

Due to the higher incidence of nasopharyngeal carcinoma (NPC) and Epstein–Barr virus (EBV) infection in the Chinese population, the differential diagnosis of lymphoepithelial carcinoma (LEC) and metastatic undifferentiated carcinoma of the parotid lymph node is clinically significant for a parotid mass. These differences make a systematic audit of SGTs in mainland Chinese patients necessary and informative.

The accurate preoperative diagnosis of SGTs depends on clinical findings, imaging characteristics and, more recently, fine needle aspiration (FNA) diagnosis. FNAs is a quick, minimally invasive procedure that has gained wide acceptance as a first-line diagnostic procedure for salivary gland lesions [9]. An intraoperative frozen section (FS) is obtained...
to confirm the diagnosis by FNA, to establish a diagnosis when FNA is nondiagnostic, and to determine the extent of tumors and assess surgical margins [10]. The accuracy of these preoperative and intraoperative diagnostic methods has been reviewed in the literature [10]. However, very few studies have discussed the comprehensive use of these methods in the management of SGTs, especially among Chinese patients with a higher incidence of NPC and EBV infection.

The objectives of this study were to determine the relative frequency and distribution of various types of SGTs in Chinese patients treated at a single cancer hospital and the clinical management and results for these patients, and to provide data for comparison with other studies in different geographic locations and/or racial populations.

Material and methods

Medical records of consecutive patients with SGTs who underwent inpatient surgery at the Department of Head & Neck Surgery, Cancer Hospital, Fudan University, Shanghai, China from December 1997 to December 2007 were reviewed. Patient information such as age, sex, tumor characteristics, and tumor pathology were recorded in a database. Histological slides were reviewed and classified by the pathologists in the same hospital according to the World Health Organization (WHO) classification system for head and neck tumors. This research was approved by the institution’s ethics committee. All the files were rechecked by the authors, and the histological slides were reviewed again by pathologists before this study. Data were analyzed using SPSS 11.0 software (SPSS, Chicago, IL, USA), and a p value < 0.05 was considered statistically significant.

Most of the patients underwent an ultrasound scan examination and computed tomography (CT) or magnetic resonance imaging (MRI) before surgery. An FNA biopsy was performed by specialized cytopathologists. When patients were diagnosed as having lymphoma by the cytopathologists, they had an outpatient biopsy only, with no further surgical intervention, and were thus excluded from the current study. FS was done for most of the patients during surgery. Since Chinese patients have a higher rate of NPC, an MRI and epipharyngoscope examination of the nasopharynx were done when necessary to differentiate original parotid LEC and parotid lymph node involvement from NPC. The final pathological reports were based on hematoxylin and eosin staining and immunohistochemical analysis. Malignant cases were discussed by a multidisciplinary team, which included surgeons, radiation oncologists, and medical oncologists, in order to develop a comprehensive management plan based on the pathology report and intraoperative assessment. Patient follow-up was carried out at outpatient clinics.

Superficial parotidectomy is the standard approach for the management of a parotid tumor. When malignancy was reported by intraoperative FS, the deep parotid lobe was further excised. For a submandibular gland tumor, a submandibular triangle dissection (submandibular gland excision with level IB dissection) was preferred. For clinical suspicion of lymph node involvement, a therapeutic neck dissection was performed. A selective neck dissection was used for malignant cases with clinical N0 neck, based on a pathological diagnosis by FS and individual surgeon’s assessment.

Results

Main clinicopathologic characteristics of SGTs

From December 1997 to December 2007, 1176 cases of SGT were treated with inpatient surgery at the Department of Head & Neck Surgery, Cancer Hospital, Fudan University, which included 289 malignant cases (24.6%) and 887 benign cases (75.4%). As shown in Table I, pleomorphic adenoma (PA) and Warthin’s tumor (WT) were the most frequent SGTs. Among the malignant cases, mucoepidermoid carcinoma (MEC, 24.6%) and adenoid cystic carcinoma (AdCC, 18.0%) were the most frequent, followed by acinic cell carcinoma (ACC, 12.1%), LEC (9.7%), and salivary duct carcinoma (SDC, 9.3%). These five most common pathological types accounted for 73.7% of malignant cases. AdCC was the most frequent pathologic type of malignant cases of submandibular, minor, and sublingual salivary glands, while MEC was the most frequent type of parotid carcinoma. With respect to minor SGTs, the palate was the most common site (51.4%), followed by the tongue (18.9%), buccal mucosa (13.5%), the floor of mouth (8.1%), and the larynx (5.4%). The median (SD) age at onset was 48 (15.6) years. There were 597 male cases and 579 female cases. However, the age at onset was older for men compared with women (50.10 ± 15.78 vs 45.66 ± 14.95, p < 0.01).

Different pathologic type distribution of primarily operated cases and recurrent or persistent cases

As shown in Tables II and III, of the 1176 cases, 1019 cases were primarily operated at our institution; another 103 were primarily operated at another hospital and had a second surgery because of recurrence
(after more than 3 months follow-up), and 54 cases were re-operated because of persistent disease (within 3 months after the first surgery).

The median age for primarily operated cases was 49 years (range 11–86), which was significantly different between benign (826 cases) and malignant tumors (193 cases) and between different malignant cases (p < 0.01) as shown in Table II. When the patients were stratified by age (≤ 50 years and > 50 years), 75% of MEC, 57.1% of AdCC, 100% of squamous cell carcinoma (SCC), and 66.1% of PA patients were under 50 years old, while 62.5% of SDC, 71.4% carcinoma ex PA (Ca ex PA), 77.8% of pleomorphic low grade adenocarcinoma (PLGA), 75.0% of EMC (epithelial-myoepithelial carcinoma), 70.0% of AC NOS (adenocarcinoma not otherwise specified), and 88.1% of WT patients were over 50 years old (p < 0.01). There was a predominance of men with WT, SDC, and LEC and a predominance of women with base cell adenoma, PA, PLGA, and lymphoma, as shown in Table II. Mean ages for persistent cases and recurrent cases were 43.61 and 42.83 years, respectively. As shown in Table III, PA accounted for 51.5% of recurrent cases followed by MEC (11.7%), LEC (11.7%), and AdCC (7.8%). MEC accounted for 35.2% of persistent cases followed by ACC (18.5%) and AdCC (16.7%).

Most frequent examinations used in the diagnostic protocol

The most frequent tools used for diagnosis were ultrasound scan (83.3%) and FNA(40.1%). CT was used in 15.7% of cases and more frequently in recurrent diseases (36.9%). As shown in Table IV, among 1019 primarily operative cases, the sensitivity (for malignancy) and specificity (for the absence of malignancy) of ultrasound scan were 58.3 and 88.6%, respectively. When malignant cases were stratified by different pathological types, the highest sensitivity was for SDC (93.8%), with lower sensitivity for ACC (33.3%) and PLGA (25.0%). The sensitivity and specificity for FNA were 87.2 and 96.7%, respectively. When different pathological types were analyzed, the highest sensitivity was for SDC (100%), AC NOS (100%), and another six cases of less frequent type (100%). Sensitivity of FNA was lower for PLGA (0%) and Ca ex PA (50%).

Intraoperative histological examinations of SGT by FS

FS was used for 94.9% of primarily operative cases performed at our department. The sensitivity and specificity were 86.9 and 99.6%, respectively. An attempt was made to type the SGTs based on FS.
Table II. Clinicopathological characteristics of salivary gland tumors primarily operated at the Cancer Hospital, Fudan University.

| Histological type              | Sex                  | Age, years (mean ± SD) | Anatomic location |
|--------------------------------|----------------------|------------------------|-------------------|
|                                | Male | Female | Parotid | Submandibular | Sublingual | Minor | Total |
| Pleomorphic adenoma            | 209 (36.9%) | 357 (63.1%) | 42.9 ± 14.0 | 377 | 177 | 0 | 12 | 566 (55.5%) |
| Warthin's tumor                | 183 (90.6%) | 19 (9.4%) | 61.3 ± 9.8 | 202 | 0 | 0 | 0 | 202 (19.8%) |
| Base cell adenoma              | 13 (37.1%) | 22 (62.9%) | 50.1 ± 10.8 | 34 | 1 | 0 | 0 | 35 (3.4%) |
| Myoepithelioma                 | 5 (50.0%) | 5 (50.0%) | 47.9 ± 10.1 | 7 | 3 | 0 | 0 | 10 (1.0%) |
| Other benign tumor             | 8 (61.5%) | 5 (38.5%) | 47.9 ± 13.5 | 13 | 0 | 0 | 0 | 13 (1.3%) |
| Mucoepidermoid carcinoma       | 18 (45.0%) | 22 (55.0%) | 39.5 ± 15.0 | 29 | 3 | 2 | 6 | 40 (3.9%) |
| Adenoid cystic carcinoma       | 15 (42.9%) | 20 (57.1%) | 46.0 ± 12.6 | 13 | 10 | 2 | 10 | 35 (3.4%) |
| Salivary duct carcinoma        | 20 (83.3%) | 4 (16.7%) | 58.1 ± 15.6 | 14 | 10 | 0 | 0 | 24 (2.4%) |
| Acinic cell carcinoma          | 12 (54.5%) | 10 (45.9%) | 51.6 ± 17.9 | 18 | 4 | 0 | 0 | 22 (2.2%) |
| Lymphoepithelial carcinoma     | 7 (63.6%) | 4 (36.4%) | 51.8 ± 16.8 | 8 | 3 | 0 | 0 | 11 (1.1%) |
| PLGA                           | 3 (33.3%) | 6 (66.7%) | 58.2 ± 11.6 | 7 | 0 | 0 | 2 | 9 (0.9%) |
| Adenocarcinoma NOS             | 5 (50.0%) | 5 (50.0%) | 58.7 ± 13.0 | 6 | 3 | 0 | 1 | 10 (1.0%) |
| Carcinoma ex PA                | 4 (57.1%) | 3 (42.9%) | 58.3 ± 10.5 | 5 | 2 | 0 | 0 | 7 (0.7%) |
| Epithelial-myoepithelial carcinoma | 2 (50.0%) | 2 (50.0%) | 59.8 ± 15.9 | 3 | 1 | 0 | 0 | 4 (0.4%) |
| Squamous cell carcinoma        | 1 (50.0%) | 1 (50.0%) | 36.5 ± 5.0 | 0 | 2 | 0 | 0 | 2 (0.2%) |
| Other malignant tumor          | 7 (77.8%) | 2 (22.2%) | 72.3 ± 9.0 | 7 | 1 | 0 | 1 | 9 (0.9%) |
| Metastatic carcinoma           | 2 (100%) | 0 (0.0%) | 58.0 ± 11.3 | 2 | 0 | 0 | 0 | 2 (0.2%) |
| Lymphoma                       | 5 (27.8%) | 13 (72.2%) | 52.8 ± 14.2 | 13 | 5 | 0 | 0 | 18 (1.8%) |
| Total                          | 519 (50.9%) | 500 (49.1%) | 48.7 ± 15.5 | 758 (74.4%) | 225 (22.1%) | 4 (0.4%) | 32 (3.1%) | 1019 |
When the pathological types of tumor reported by FS were compared with the final pathological diagnosis, PA (97.1%) and WT (99.0%) had the highest concordance. For malignant cases, ACC had the highest concordance (85.7%) followed by SDC (70.0%), MEC (66.7%), and AdCC (61.3%). None of the PLGA (\(n=9\)) and Ca ex PA (\(n=7\)) cases were diagnosed correctly based on the FS.

### Treatment protocols and results

The most used surgical procedure for benign parotid and submandibular tumors was superficial parotidectomy and excision of submandibular gland. Among 173 cases of salivary gland carcinoma (Table II), all malignant cases (excluded metastatic carcinoma and lymphoma) that were primarily operated at our department, 80.9% (89/110) of parotid carcinomas had a total parotidectomy, 87.2% of submandibular carcinomas (34/39) had a level Ib dissection, 48.6% (84/173) of cases underwent lateral neck dissection, and 48% (83/173) of cases underwent postoperative radiation therapy. For parotid, submandibular, sublingual, and minor salivary gland carcinoma, the percentages of pathologic lymph node involvement (pN+) were 20.0%, 35.9%, 25.0, and 35%, respectively. The percentages of pathologic TNM stage were 23.7% for stage I, 32.9% for stage II, 17.3% for stage III, and 26.1% for stage IV. Active follow-up was completed in 98.3% of malignant cases and the median follow-up time was 30 months (range 1–140 months). The 5-year overall survival rate was 88%. The 5-year overall survival rates for stage I, stage II, stage III, and stage IV were 100, 97, 75, and 73%, respectively (\(p < 0.01\)).

### Discussion

This is the first study to evaluate patterns of SGTs operated in a Chinese cancer hospital during 1997–2007 according to the WHO 2005 classification that presents a detailed evaluation of >1000 cases by pathologic classification, diagnostic methods, and treatment methods and results. Clinical epidemiological data on SGTs from various parts of the world can be helpful in better understanding the biology, clinical characteristics, and management protocols of SGT. Most of the SGTs are treated by oral and maxillofacial surgeons and head and neck surgeons in China, while none of the published literature on SGTs from China was from head neck surgeons [3,6,7]. When compared with our results from head and neck surgeons, the reported higher frequency of AdCC and PLGA in the published literature on mainland Chinese patients is due to the fact that more intraoral minor SGTs are operated by maxillofacial surgeons than head and neck surgeons.

The most common benign and malignant SGTs in our study were the same as in the worldwide literature – PA followed by WT and MEC followed by AdCC [11,12]. New information in this study includes the observation of a higher rate of LEC (9.7%) and SDC (9.3%). Globally, SDC accounts for 0.2–5.1% of salivary gland carcinomas as reported in Table III. Clinicopathological characteristics of reoperative cases of salivary gland tumor.

| Pathological type               | Reason for reoperation | Anatomic location |
|--------------------------------|------------------------|-------------------|
|                                | Recurrent Persistent   | Parotid Submandibular Sublingual Minor Total |
| Pleomorphic adenoma            | 53 1                   | 45 9 0 0 0 54     |
| Warthin’s tumor                | 3 0                    | 3 0 0 0 0 3       |
| Myoepithelioma                 | 1 1                    | 2 0 0 0 0 2       |
| Other benign tumor             | 1 1                    | 2 0 0 0 0 2       |
| Mucoepidermoid carcinoma       | 12 19                  | 26 3 0 2 3 31     |
| Adenoid cystic carcinoma       | 8 9                    | 2 10 2 3 17      |
| Salivary duct carcinoma        | 0 3                    | 2 1 0 0 3          |
| Acinic cell carcinoma          | 3 10                   | 13 0 0 0 0 13     |
| Lymphoepithelial carcinoma     | 12 5                   | 14 3 0 0 17       |
| Adenocarcinoma NOS             | 2 2                    | 2 2 0 0 4        |
| Carcinoma ex PA                | 2 1                    | 3 0 0 0 3        |
| Other malignant tumor          | 5 1                    | 5 1 0 0 6        |
| Metastatic carcinoma           | 1 1                    | 2 0 0 0 2        |
| Total                          | 103 54                 | 121 29 2 5 157    |

Table III. Clinicopathological characteristics of reoperative cases of salivary gland tumor.
Table IV. Results of ultrasound scan, fine needle aspiration, and frozen section of salivary gland tumor primarily operated at the Cancer Hospital, Fudan University.

| Pathological type            | Ultrasound scan | Fine needle aspiration | Frozen section |
|------------------------------|-----------------|------------------------|----------------|
|                              | Benign | Malignant | Unclassified | Missed | Benign | Malignant | Unclassified | Missed | Benign | Malignant | Unclassified | Missed | Total |
| Pleomorphic adenoma          | 306    | 43        | 73           | 144     | 179    | 4         | 37           | 346     | 557    | 0         | 3           | 6       | 566    |
| Warthin’s tumor              | 109    | 12        | 39           | 42      | 76     | 1         | 5            | 120     | 198    | 1         | 2           | 1       | 202    |
| Base cell adenoma            | 23     | 3         | 5            | 4       | 5      | 1         | 6            | 23      | 32     | 0         | 3           | 0       | 35     |
| Myoepithelioma               | 7      | 0         | 0            | 3       | 3      | 2         | 0            | 5       | 8      | 2         | 0           | 0       | 10     |
| Other benign tumor           | 7      | 0         | 2            | 4       | 0      | 1         | 2            | 10      | 11     | 0         | 2           | 0       | 13     |
| Mucoepidermoid carcinoma     | 14     | 10        | 3            | 13      | 4      | 11        | 5            | 20      | 1      | 30        | 2           | 7       | 40     |
| Adenoid cystic carcinoma     | 5      | 13        | 6            | 11      | 3      | 16        | 0            | 16      | 4      | 23        | 4           | 4       | 35     |
| Salivary duct carcinoma      | 1      | 15        | 3            | 5       | 0      | 20        | 0            | 4       | 0      | 10        | 0           | 14      | 24     |
| Acinic cell carcinoma        | 10     | 5         | 3            | 4       | 2      | 10        | 3            | 7       | 0      | 19        | 2           | 1       | 22     |
| Lymphoepithelial carcinoma   | 1      | 3         | 4            | 3       | 0      | 6         | 3            | 2       | 2      | 3         | 0           | 6       | 11     |
| PLGA                         | 3      | 1         | 2            | 3       | 1      | 0         | 3            | 5       | 4      | 4         | 0           | 1       | 9      |
| Adenocarcinoma NOS           | 4      | 4         | 1            | 1       | 0      | 3         | 0            | 7       | 0      | 6         | 0           | 4       | 10     |
| Carcinoma ex PA              | 0      | 1         | 1            | 5       | 1      | 1         | 1            | 4       | 3      | 4         | 0           | 0       | 7      |
| Epithelial-myoepithelial carcinoma | 1  | 2         | 1            | 0       | 1      | 2         | 0            | 1       | 0      | 2         | 0           | 2       | 4      |
| Squamous cell carcinoma      | 1      | 1         | 0            | 0       | 0      | 1         | 0            | 1       | 0      | 1         | 0           | 1       | 2      |
| Other malignant tumor        | 2      | 5         | 1            | 1       | 0      | 6         | 0            | 3       | 1      | 5         | 0           | 3       | 9      |
| Metastatic carcinoma         | 0      | 0         | 1            | 1       | 0      | 1         | 0            | 1       | 0      | 0         | 1           | 1       | 2      |
| Lymphoma                     | 3      | 3         | 8            | 4       | 0      | 5         | 2            | 11      | 3      | 11        | 3           | 1       | 18     |
| Total                        | 497    | 121       | 152          | 249     | 275    | 91        | 67           | 586     | 824    | 121       | 22          | 52      | 1019   |
The diagnostic benefi t is generally known within 30 min of the procedure, repeat FNA is easily done. This makes FNA as performed at our center informative and accurate. In some cases, such as PLGA, Ca ex PA, and cystic lesions, the accuracy is lower, and the results should be confirmed with imaging studies and by FS. The reported sensitivity of FS ranges from 40% to 100% [18]. The sensitivity and specificity of FS in our reports were 86.9 and 99.6%, respectively. Beyond identifying or excluding malignancy at the time of surgery, pathologic typing of the salivary gland lesion is also important to determine the operative extent, which is better than FNA [18]. FNA and FS have complementary uses in the management of salivary gland lesions and their more frequent use will change the management of some special cases of SGTs, such as ACC.

With respect to therapeutic methods and results, postoperative radiation and neck dissection are two controversial issues. Radiotherapy is often used in an adjuvant role following definitive surgery for large tumors, high grade tumors, closed/incomplete excisions, and perineural or vascular invasion. In Italy, postoperative radiotherapy is used in 88% of cases [11]. In our series, the malignant cases were discussed by a multidisciplinary team to outline a comprehensive management plan based on the pathologic report and intraoperative assessment; 48% of cases received postoperative radiation therapy. Neck dissection was performed for 48.6% of cases at our department, and 20% of cases were pathologic pN+. The 5-year overall survival (88%) of this series of patients exceeds treatment results reported elsewhere in the literature (46–81%) [19]. The better treatment results may be due to the good diagnostic accuracy of FNA and FS in our hands, which helps us with treatment planning. Neck dissections and postoperative radiation for elective patients can also improve the treatment results. If the accuracy of preoperative or intraoperative grade diagnosis of SGTs is low, elective neck dissection has been recommended for all the parotid cancer patients [20].

Conclusion

This investigation is the first to describe the clinicopathological data of SGTs treated by head and neck surgeons with a larger numbers of cases during a recent 10-year period. We found that Chinese patients have a higher rate of LEC and SDC. Comprehensive use of imaging techniques, FNA, and FS will improve the diagnostic accuracy. Neck dissection and postoperative radiation for selected patients can further improve the treatment results for salivary gland carcinoma.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

[1] Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licirri L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol 2010;74:134–48.

[2] Luukkan H, Klemi P, Leivo I, Koivunen P, Laranne J, Makitie A, et al. Salivary gland cancer in Finland 1991–96: an evaluation of 237 cases. Acta Otolaryngol 2005;125:207–14.

[3] Li LJ, Li Y, Wen YM, Liu H, Zhao HW. Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol 2008;44:187–92.
[4] Lin CC, Tsai MH, Huang CC, Hua CH, Tseng HC, Huang ST. Parotid tumors: a 10-year experience. Am J Otolaryngol 2008;29:94–100.

[5] Lim LH, Chao SS, Goh CH, Ng CY, Goh YH, Khin LW. Parotid gland surgery: 4-year review of 118 cases in an Asian population. Head Neck 2003;25:543–8.

[6] Yu GY, Li ZL, Ma DQ, Zhang Y. Diagnosis and treatment of epithelial salivary gland tumours in children and adolescents. Br J Oral Maxillofac Surg 2002;40:389–92.

[7] Tian Z, Li L, Wang L, Hu Y, Li J. Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg 2009;39:235–42.

[8] Wang D, Li Y, He H, Liu L, Wu L, He Z. Intraoral minor salivary gland tumors in a Chinese population: a retrospective study on 737 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:94–100.

[9] Hay A, Pai I, Pitkin L, Williamson P, Wilson P, Deery A. Value of fine needle aspiration cytology in head and neck lymphoma: experience in a head and neck cancer unit in the United Kingdom. Acta Otolaryngol 2011;131:1226–31.

[10] Seethala RR, LiVolsi VA, Baloch ZW. Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of lesions of the parotid gland. Head Neck 2005;27:217–23.

[11] Fiorella R, Di Nicola V, Fiorella ML, Spinelli DA, Coppola F, Luperto P, et al. Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital 2005;25:182–90.

[12] Koivunen P, Suutala L, Schorsch I, Jokinen K, Alho OP. Malignant epithelial salivary gland tumors in northern Finland: incidence and clinical characteristics. Eur Arch Otorhinolaryngol 2002;259:146–9.

[13] Takahama Junior A, Almeida OP, Kowalski LP. Parotid neoplasms: analysis of 600 patients attended at a single institution. Braz J Otorhinolaryngol 2009;75:497–501.

[14] Ito FA, Ito K, Vargas PA, de Almeida OP, Lopes MA. Salivary gland tumors in a Brazilian population: a retrospective study of 496 cases. Int J Oral Maxillofac Surg 2005;34:533–6.

[15] Subhashraj K. Salivary gland tumors: a single institution experience in India. Br J Oral Maxillofac Surg 2008;46:635–8.

[16] Friborg J, Koch A, Wohlfarth J, Storm HH, Melbye M. Cancer in Greenlandic Inuit 1973–1997: a cohort study. Int J Cancer 2003;107:1017–22.

[17] Rajwanshi A, Gupta K, Gupta N, Shukla R, Srinivasan R, Nijhawan R, et al. Fine-needle aspiration cytology of salivary glands: diagnostic pitfalls revisited. Diagn Cytopathol 2006;34:580–4.

[18] Tan LG, Khoo ML. Accuracy of fine needle aspiration cytology and frozen section histopathology for lesions of the major salivary glands. Ann Acad Med Singapore 2006;35:242–8.

[19] Valstar MH, van den Brekel MW, Smeele LE. Interpretation of treatment outcome in the clinically node-negative neck in primary parotid carcinoma: a systematic review of the literature. Head Neck 2010;32:1402–11.

[20] Kawata R, Koutetsu L, Yoshimura K, Nishikawa S, Takenaka H. Indication for elective neck dissection for N0 carcinoma of the parotid gland: a single institution’s 20-year experience. Acta Otolaryngol 2010;130:286–92.